Researcher

Xinyi Su is the Acting Executive Director and Senior Principal Investigator at the Institute of Molecular and Cell Biology (IMCB). She completed her medical and PhD degrees at the University of Cambridge and joined IMCB in 2016. Su practices ophthalmology as a Senior Consultant in Vitreo-retinal surgery at the National University Hospital (NUH), Singapore. She also holds joint appointments as Research Director at the Department of Ophthalmology, National University of Singapore (NUS), and Clinician-Scientist at the Singapore Eye Research Institute (SERI). Su’s research interests focus on harnessing biomaterial, regenerative stem-cell, and nucleic acid technologies for the treatment of age-related retinal degenerative disease. Her research has been published in many top-tier scientific journals and she has obtained a career total of over SGD25 million in competitive research funding. Su is also the recipient of multiple global and national awards, including the Susan Lim Outstanding Stem Cell Young Investigator Award (2022) and National Medical Research Council Clinician Scientist Award (2022).